Breathomix, developed a technology, BreathBase, that analyzes the complete mixture of molecules within exhaled breath and returns a diagnostic answer within seconds in the doctor’s office. The data allows doctors to diagnose and subtype lung disease, such as asthma, COPD and lung cancer. BreathBase analyzes patient’s exhaled breath in real-time based on advanced signal processing and an extensive online reference database, infused with AI.
Diagnosing pulmonary diseases is often difficult and time-consuming. Treatment strategies are mostly based on trial and error which leads to increased mortality and hospitalization rates, unnecessary loss of patients’ quality of life, wasted time and insurer money. Now it is possible for patients to receive the right treatment during their first visit to the doctor. With the data instantly at their fingertips, physicians can provide on the spot care using BreathBase. Beyond that, AI can provide insights that are predictive in nature, identifying individuals who are likely to respond to a specific treatment or maybe will develop a specific lung disease in the near future, helping doctors provide the best treatment.
The Dutch startup has an agreement with CBusineZ, a foundation related to CZ insurance company in Netherlands. Together with CBusineZ they push the technology to the market through selected clinical partners.
Immediate results with >90% accuracy
Breathomix has developed BreathBase for the early detection of lung cancer, to identify chronic airway disease such as asthma and COPD and to predict response to therapy. The solution has broad applications and has a solid value proposition towards physicians, general practitioners and health insurers. BreathBase is the first non-invasive, easy to use and cheap diagnostic tool available that provides immediate results with >90% accuracy in the doctor’s office. On top of that it is the only on-line solution in the field, which makes the technology easily scalable, and more so than any other system.
Performed studies with the BreathBase solution range from extensive technical validation studies, pilot studies and prospective observation">
Want to continue reading?
Sign up for our newsletter to read the full article and receive the latest news about innovation in insurance and Insurtech straight to your mailbox every week. Already signed up before?
- Join over 20,000 other insurance executives to receive the latest innovations in insurance
- Be the first to read our Insurtech editorials
- Stay tuned for the latest community news
- Get access to exclusive offers!